US Bancorp’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $856K | Buy |
5,080
+1,692
| +50% | +$251K | ﹤0.01% | 1273 |
|
|
2026
Q1 | $446K | Sell |
3,388
-44
| -1% | -$5.84K | ﹤0.01% | 1564 |
|
|
2025
Q4 | $487K | Sell |
3,432
-81
| -2% | -$11.7K | ﹤0.01% | 1557 |
|
|
2025
Q3 | $493K | Sell |
3,513
-589
| -14% | -$79.8K | ﹤0.01% | 1510 |
|
|
2025
Q2 | $516K | Buy |
4,102
+373
| +10% | +$42.8K | ﹤0.01% | 1487 |
|
|
2025
Q1 | $412K | Sell |
3,729
-446
| -11% | -$56.5K | ﹤0.01% | 1598 |
|
|
2024
Q4 | $570K | Buy |
4,175
+311
| +8% | +$38.5K | ﹤0.01% | 1428 |
|
|
2024
Q3 | $445K | Sell |
3,864
-1,709
| -31% | -$234K | ﹤0.01% | 1578 |
|
|
2024
Q2 | $767K | Buy |
5,573
+614
| +12% | +$84.2K | ﹤0.01% | 1239 |
|
|
2024
Q1 | $684K | Sell |
4,959
-926
| -16% | -$126K | ﹤0.01% | 1302 |
|
|
2023
Q4 | $775K | Buy |
5,885
+522
| +10% | +$60.1K | ﹤0.01% | 1250 |
|
|
2023
Q3 | $603K | Sell |
5,363
-5,606
| -51% | -$590K | ﹤0.01% | 1279 |
|
|
2023
Q2 | $1.03M | Sell |
10,969
-12,669
| -54% | -$1.24M | ﹤0.01% | 1055 |
|
|
2023
Q1 | $2.39M | Buy |
23,638
+696
| +3% | +$72.4K | ﹤0.01% | 740 |
|
|
2022
Q4 | $2.74M | Sell |
22,942
-6,229
| -21% | -$730K | ﹤0.01% | 708 |
|
|
2022
Q3 | $3.1M | Sell |
29,171
-2,040
| -7% | -$207K | 0.01% | 632 |
|
|
2022
Q2 | $3.04M | Buy |
31,211
+96
| +0.3% | +$8.86K | 0.01% | 661 |
|
|
2022
Q1 | $2.92M | Buy |
31,115
+9,524
| +44% | +$807K | ﹤0.01% | 741 |
|
|
2021
Q4 | $1.84M | Sell |
21,591
-8,830
| -29% | -$812K | ﹤0.01% | 948 |
|
|
2021
Q3 | $2.92M | Sell |
30,421
-413
| -1% | -$39K | 0.01% | 745 |
|
|
2021
Q2 | $3M | Buy |
30,834
+1,740
| +6% | +$167K | 0.01% | 744 |
|
|
2021
Q1 | $2.83M | Buy |
29,094
+7,366
| +34% | +$772K | 0.01% | 726 |
|
|
2020
Q4 | $2.08M | Buy |
21,728
+3,549
| +20% | +$343K | ﹤0.01% | 790 |
|
|
2020
Q3 | $1.75M | Buy |
18,179
+13,704
| +306% | +$1.59M | ﹤0.01% | 786 |
|
|
2020
Q2 | $546K | Buy |
4,475
+655
| +17% | +$72.4K | ﹤0.01% | 1242 |
|
|
2020
Q1 | $330K | Buy |
3,820
+11
| +0.3% | +$1.08K | ﹤0.01% | 1420 |
|
|
2019
Q4 | $410K | Buy |
3,809
+685
| +22% | +$71.7K | ﹤0.01% | 1472 |
|
|
2019
Q3 | $281K | Buy |
3,124
+250
| +9% | +$23.4K | ﹤0.01% | 1649 |
|
|
2019
Q2 | $244K | Sell |
2,874
-12
| -0.4% | -$985 | ﹤0.01% | 1744 |
|
|
2019
Q1 | $254K | Buy |
2,886
+1,609
| +126% | +$134K | ﹤0.01% | 1694 |
|
|
2018
Q4 | $91K | Buy |
1,277
+479
| +60% | +$45.9K | ﹤0.01% | 2174 |
|
|
2018
Q3 | $99K | Buy |
798
+28
| +4% | +$3.18K | ﹤0.01% | 2225 |
|
|
2018
Q2 | $75K | Buy |
770
+54
| +8% | +$4.83K | ﹤0.01% | 2372 |
|
|
2018
Q1 | $59K | Buy |
716
+318
| +80% | +$26.9K | ﹤0.01% | 2506 |
|
|
2017
Q4 | $31K | Sell |
398
-534
| -57% | -$36.4K | ﹤0.01% | 2786 |
|
|
2017
Q3 | $57K | Buy |
932
+326
| +54% | +$17.2K | ﹤0.01% | 2512 |
|
|
2017
Q2 | $28K | Buy |
606
+314
| +108% | +$15.2K | ﹤0.01% | 2773 |
|
|
2017
Q1 | $12K | Sell |
292
-173
| -37% | -$7.41K | ﹤0.01% | 2990 |
|
|
2016
Q4 | $18K | Buy |
465
+440
| +1,760% | +$19.9K | ﹤0.01% | 2877 |
|
|
2016
Q3 | $1K | Sell |
25
-503
| -95% | -$25.1K | ﹤0.01% | 3457 |
|
|
2016
Q2 | $24K | Sell |
528
-458
| -46% | -$21.1K | ﹤0.01% | 2729 |
|
|
2016
Q1 | $39K | Sell |
986
-1,577
| -62% | -$62.6K | ﹤0.01% | 2501 |
|
|
2015
Q4 | $145K | Buy |
2,563
+1,437
| +128% | +$73K | ﹤0.01% | 1858 |
|
|
2015
Q3 | $45K | Sell |
1,126
-293
| -21% | -$14.2K | ﹤0.01% | 2508 |
|
|
2015
Q2 | $68K | Buy |
1,419
+73
| +5% | +$3.1K | ﹤0.01% | 2365 |
|
|
2015
Q1 | $54K | Buy |
1,346
+1,146
| +573% | +$41K | ﹤0.01% | 2503 |
|
|
2014
Q4 | $4K | Hold |
200
| – | – | ﹤0.01% | 3327 |
|
|
2014
Q3 | $3K | Hold |
200
| – | – | ﹤0.01% | 3326 |
|
|
2014
Q2 | $3K | Hold |
200
| – | – | ﹤0.01% | 3327 |
|
|
2014
Q1 | $3K | Hold |
200
| – | – | ﹤0.01% | 3302 |
|
|
2013
Q4 | $2K | Hold |
200
| – | – | ﹤0.01% | 3293 |
|
|
2013
Q3 | $2K | Hold |
200
| – | – | ﹤0.01% | 3192 |
|
|
2013
Q2 | $3K | Buy |
+200
| New | +$2.46K | ﹤0.01% | 3093 |
|
Other funds holding NBIX
US Bancorp's NBIX Position: Q2 2026 in Review
US Bancorp increased its Neurocrine Biosciences (NBIX) stake by 50% in Q2 2026, buying an estimated $251K and bringing the position to 5,080 shares worth $856K. The position accounts for ﹤0.01% of the portfolio, ranked #1273.
US Bancorp first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.1M in Q3 2022. 772 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- US Bancorp held 5,080 shares of Neurocrine Biosciences worth $856K as of Q2 2026.
- US Bancorp bought 1,692 Neurocrine Biosciences shares in Q2 2026, an estimated $251K.
- Neurocrine Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #1273 holding.
- US Bancorp first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- US Bancorp's Neurocrine Biosciences position peaked at $3.1M in Q3 2022.
- 772 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.